Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680037 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
A Phase 1 study of B-cell Mediated Autoimmune Disorders, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 8
- Study locations
NCT06680037: Recruiting Phase 1 study of B-cell Mediated Autoimmune Disorders, sponsored by TG Therapeutics.
NCT06680037 is a Phase 1 study of B-cell Mediated Autoimmune Disorders that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 32 participants. The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06680037, a Phase 1 study of B-cell Mediated Autoimmune Disorders, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 8
- Study locations
Study Summary
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Conditions Studied
Interventions
- DRUG Azercabtagene zapreleucel (azer-cel)
Study Locations (8)
New York
- TG Therapeutics Investigational Trial Site - New York
- TG Therapeutics Investigational Trial Site - Rochester
Ohio
- TG Therapeutics Investigational Trial Site - Cleveland
- TG Therapeutics Investigational Trial Site - Columbus
California
- TG Therapeutics Investigational Trial Site - La Jolla
Kentucky
- TG Therapeutics Investigational Trial Site - Lexington
Michigan
- TG Therapeutics Investigational Trial Site - Ann Arbor
Nebraska
- TG Therapeutics Investigational Trial Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06680037
The ClinicalTrials.gov registry entry for NCT06680037 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Mediated Autoimmune Disorders appearing as the primary indexed condition, and to 1 intervention - of which Azercabtagene zapreleucel (azer-cel) is the first listed.
NCT06680037 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT06680037 about?
NCT06680037 is a clinical study titled "A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders". The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
What is the current status of trial NCT06680037?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-05-06. Estimated completion is 2029-01-01.
What conditions does trial NCT06680037 study?
This clinical trial studies the following conditions: B-cell Mediated Autoimmune Disorders.
What interventions are being tested in trial NCT06680037?
The interventions under investigation include: Azercabtagene zapreleucel (azer-cel) (DRUG).
Who is sponsoring clinical trial NCT06680037?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06680037 being conducted?
This trial has 8 study locations across California, Kentucky, Michigan, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.